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Abstract 
Background: Recently alternative therapies such as the use of diode laser therapy have been introduced for recu-
rrent herpes labial infection. The aim of this study was to evaluate the effectiveness of diode laser for treatment of 
recurrent herpes labialis. 
Material and Methods: This was single-blind randomized clinical trial to evaluate the efficacy of diode laser for the 
treatment of recurrent herpes labial. In total, 60 patients whit recurrent herpes simplex labialis were selected and 
randomly divided in to three groups. 20 patients received treatment whit diode laser (at a wavelength of 870 nm, 
energy density 4.5 j/cm2), 20 patients were treated with acyclovir cream 5%, 20 patients received treatment with 
laser-off (placebo). The end point was lesions crusting. Data analyzed by Tukey HSD Test and One-way ANOVA 
(at a significance level of 0.05) in SPSS-20 software.
Results: The mean length of recovery time (day) in the laser, off laser, and acyclovir groups was 2.20±0.41, 4.30±1.03, 
and 3.4±1.142, respectively. There is a significant difference between three groups in this regard (P<0.0001). The 
mean duration of pain (day) was 1.35±0.74, 2.65±1.27, and 2.30±0.92 for laser, off laser, and acyclovir groups, 
respectively (P<0.0001). 
Conclusions: Treatment with diode laser reduced the length of recovery time and pain severity faster than treatment 
with acyclovir cream.
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Introduction
Recurrent herpes labialis (RHL) occurs in 20% to 40% 
of young adult population. The lesions have prodromal 
symptoms, including itching, tingling or burning in 
50% of cases and eventually develop papules, vesicles, 
ulcers, and crust. The pain often exists during the first 
two days (1). Internal or external stimuli such as stress, 
immunosuppression, high fever, trauma, and ultraviolet 
light can trigger recurrences (2). The lesions usually re-
solve within 7 to 10 days (3).
Although RHL is a self-limiting condition, the use of 
topical antiviral medications reduces viral shedding and 
infectivity. These agents also decrease pain level, lesion 
size and duration of symptoms (1). Antiviral medica-
tions such as acyclovir cream 5% and docosanol cream 
10% can be beneficial if initiated during the onset of le-
sions. Since these agents have relatively a short half-life, 
they should be used several times throughout the day 
(1). Risk of drug nephrotoxicity should be considered 
for systemic administration (4,5).
Low level laser therapy (LLLT) has been considered as a 
possible treatment for herpes labialis in recent years. The 
laser phototherapy has analgesic and anti-inflammatory 
properties and stimulates tissue regeneration, fibroblast 
proliferation and neo-vascularization potential (6).
Many studies have examined the influence of LLLT 
wavelengths on herpes labialis.
Dougal and Lee (2) assigned 87 patients with herpes la-
bialis randomly in two groups. They used low level laser, 
1072 nm, for the experimental group. The control group 
was treated with the laser turned off. The experimental 
group showed a significant reduction in healing time.
Muñoz Sanchez et al. (7) conducted a study in 2012 in 
which they compared the effect of LLLT, 670 nm, on 
herpes labialis with acyclovir. They reported that LLLT 
was an effective therapy with no side effects.
This study aimed to evaluate the effect of Low level la-
ser therapy on the treatment of patients with herpes la-
bialis compared to acyclovir cream.
Materials and Methods
This single-blind randomized clinical trial was carried 
out on 60 patients with herpes labialis referring to the 
oral medicine department of Zahedan university of me-
dical science, Before entering the study, patients were 
informed regarding the purpose of this study and pro-
vided a signed consent to participate in this study. The 
protocol was approved by Ethical Committee of Zahe-
dan University of medical science (code 7030).  The par-
ticipants had no systemic diseases or oral lesions and did 
not take other medications during the study. All patients 
had herpes labialis lesions developed 0-36 hours before 
the study.
The patients were randomly divided into three 20-mem-
ber groups. The three groups were matched for age and 
sex. The first group was treated using acyclovir cream 
(5%) 5 times per day. 
The second group was treated with diode laser [(LO7 
probe, Mustang 2000, Russia), wavelength 870nm, ener-
gy density 4.5j/cm2, frequency 600Hz and maximum 
pulse radiation power 80W for a minute/ day]. The tip of 
the probe was held 6-8mm from the lesion.
In the third group, laser therapy was performed using a 
turned-off device. It should be noted that we used the 
protective eyewear for the safety of patients. Patients 
were not informed about the possible benefits of laser 
treatment.
The treatment was performed by an oral medicine spe-
cialist, and the patients were examined on daily basis 
using a dental chair light source. Intended parameters in-
cluded lesion size, pain level and length of time for crust 
development. The examination was done by an oral me-
dicine assistant who was blinded to treatment.
The lesion size was determined by measuring the two 
main diameters of the lesion in square millimeters using 
a transparent graph paper.
The pain intensity was evaluated based on the visual 
analogue scale (VAS) before treatment and at each fo-
llow-up session. According to this scale, 0 represented 
no pain and 10 represented the most severe pain ever 
experienced. Crust formation and erythema resolution 
were healing signs. The aforementioned information 
was recorded in relevant data sheets. 
Data analyzed by Tukey HSD Test and One-way ANOVA 
(at a significance level of 0.05) in SPSS-20 software.
Results 
This study aimed to compare the effect of diode laser 
on herpes labialis with acyclovir. Sixty participants were 
divided into three groups. The laser group consisted of 
15 males (75%) and 5 females (25%) with the mean age 
of 31.30±10.032. The turned-off laser group consisted of 
15 males (75%) and 5 females (25%) with the mean age 
of 32.85±6.808. The acyclovir-treated group consisted 
of 14 males (70%) and 6 females (30%) with the mean 
age of 31.35±6.862. The mean age and the sex distribu-
tion were similar in all three groups. 
The average area of the lesion in laser, turned-off la-
ser and acyclovir-treated groups was 25.55±15.99mm2, 
25.75±12.74mm2, and 25.90±15.05mm2, respectively. 
There was no statistically significant difference between 
these groups (p=0.997). In addition, the pain level ba-
sed on VAS was 3.65±2.581 in laser group, 3.50±2.705 
in turned-off laser group, and 3.50±2.065 in acyclovir-
treated group before the treatment, and no statistically 
significant difference was observed among the three 
groups (p=0.976).
One-way ANOVA test demonstrated that there was a sta-
tistically significant difference among the three groups 
during the treatment process in terms of pain intensity 
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(Table 1). Two-group assessment using Tukey HSD 
showed a significant difference among the groups in 
terms of pain intensity. 
One-way ANOVA test for the mean and standard devia-
tion of lesion area showed that there was a statistically 
significant difference among the three groups (Table 2). 
Two-group assessment using Tukey HSD showed a sig-
nificant difference among the groups in terms of lesion 
area. Table 2 demonstrates the mean and standard de-
viation of lesion area in the three evaluated groups on 
different days of treatment.
It is noteworthy that in the turned-off laser group on the 
fifth and sixth days, only 7 and 2 patients were still under 
treatment, respectively. The other participants’ lesions 
had developed crust on the fourth day.
In the acyclovir group, on the fourth, fifth, and sixth 
days, only 5, 5, and 1 patient were still under treatment, 
respectively considering their lesion, and the other pa-
tients of this group had recovered during the first three 
days of treatment.
As table 3 shows, the mean recovery time (day) was 
2.20±0.41 in the laser group, 4.30±1.03 in the turned-off 
laser group and 3.4±1.142 in the acyclovir group, which 
showed a statistically significant difference (p<0.0001).
In addition, the mean treatment duration of pain in terms 
of days in the three groups of laser, turned-off laser, and 
acyclovir was 1.35±0.74, 2.65±1.27, and 2.30±0.92, res-
pectively, which showed a statistically significant diffe-
rence (p<0.0001). Tukey HSD test also showed that the 
two-group difference was significant.
Discussion 
Recurrent herpes labialis infection occurs in more than 
one fifth of young adult population. Transmission may 
occur via contact with an infected person. The virus 
remains in a latent state in neural tissues, and internal 
or external stimuli such as stress, immunosuppression, 
high fever, trauma, and ultraviolet light can trigger re-
currences (2).
Herpes labialis not only causes pain and discomfort, but 
also periods of feeling sick during the infection which 
can affect a person’s work and social activities (8).
Effective antiviral medications on herpes labialis such 
as acyclovir have the most influence while using at the 
onset of the lesion; however, late treatment is associa-
ted with prolonged symptoms and persistent lesions. In 
addition, these agents should be administered several ti-
mes on consecutive days that can have even sometimes 
interactions with other medications (2).
Acyclovir is an effective treatment for herpes labialis 
with a short half-life, whereas famciclovir and vala-
cyclovir have longer half-lives; however, they are not 
Day
Pain intensity
First day
Mea ± SD
Second day
Mean± SD
Third day
Mean± SD
Fourth day
Mean± SD
Fifth day
Mean± SD
laser 3.65±2.58 0.85±0.99 0.05±0.22 0.00±0.00 0.00±0.00
Laser off 3.50±2.70 3.20±2.84 1.75±1.83 0.25±0.44 0.00±0.00
acyclovir 3.50±2.06 2.55±1.82 0.85±1.09 0.00±0.00 0.00±0.00
p-value 0.976 0.002 0.0001> - -
Table 1: Pain intensity in the three groups on different days of treatment.
Day
Group
First day
Mean ± SD
Second day
Mean ± SD
Third day
Mean ± SD
Fourth day
Mean ± SD
Fifth day
Mean ± SD
Sixth day
Mean ± SD
Laser 25.55±15.99 22.25±15.48 6.80±14.76 0.00±0.00 0.00±0.00 0.00±0.00
Laser off 25.75±12.74 25.75±12.74 23.60±12.00 21.20±12.65 7.85±16.25 1.35±4.18
Acyclovir 25.90±15.05 24.90±14.61 21.00±15.54 9.10±16.77 8.85±16.25 2.25±10.09
p-value 0.997 0.724 0.001 - - -
Table 2: Mean and standard deviation of lesion area in the three evaluated groups on different days of treatment.
Variant Laser Laser off Acyclovir P-Value
recovery time(day) 2.20±0.41 4.30±1.03 3.40±1.042 0.0001>
Duration of pain(day) 1.35±0.74 2.65±1.25 2.30±0.92 0.0001>
Table 3: Comparison of clinical characteristics in three groups.
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available as topical agents. Some acyclovir and famci-
clovir-resistant strains of HSV have emerged mainly due 
to cavalier use of these agents. In addition, systemic me-
dications can increase the risk of nephrotoxicity in case 
the patient gets dehydrated (4,5).
In general, these difficulties with conventional medica-
tions have directed investigators toward other therapeutic 
approaches. Attention has been given to laser therapy as 
a new treatment method for herpes labialis. 
Low level laser therapy has physiological effects such 
as anti-inflammatory, analgesic and healing-stimulating 
characteristics (6). 
Many studies have evaluated different wavelengths of 
low level laser on herpes labialis (7-10).
This study also aimed to evaluate the effect of diode la-
ser on treatment of patients with herpes labialis compa-
red with acyclovir. The low level laser therapy (LLLT) 
significantly decreased the healing time, and pain inten-
sity compared to acyclovir and turned-off laser groups, 
which is consistent with previous studies.
In a study conducted in 2013 by Dougal and Lee (2), the 
effect of diode laser (1072 nm) on herpes labialis was 
assessed. The results showed that the crust time and hea-
ling time for herpes labialis decreased in the laser group 
compared to the control group.
In a study conducted in 2006 by Hargate et al. (9), the 
effect of diode laser (1072nm) on herpes labialis was 
assessed. The results showed that the mean crust time 
was two days for the experimental group and 2.88 days 
for the control one. The mean healing time was 6.33 and 
9.40 days for the experimental and control groups, res-
pectively.
Eduardo et al. (10) conducted a study in 2012 with a 3 
year follow-up which showed that LLLT as a prophylac-
tic treatment for recurrent herpes labialis not only redu-
ced lesion frequency, but also made healing quicker and 
symptoms less intense.
De Carvalho et al. (3) (2010) reported that Ga-Al-As la-
ser (780nm) (one weekly session, 10 sessions in total) 
reduced the lesion size and inflammation.
Marotti et al. (11) conducted a study in 2009 using dio-
de laser, 660nm, to treat patients with herpes labialis in 
the vesicle stage. They suggested that laser therapy re-
duced recurrence rates, relieved symptoms and has no 
side effects.
Several mechanisms have been proposed for therapeutic 
effects of LLLT. Laser induces more ATP production in 
mitochondria and reduces cellular oxygen consumption. 
Levels of serotonin and endorphins increase, prosta-
glandin production decreases, and cytokine and growth 
factor expression promotes which eventually causes in-
flammation reduction and healing process promotion. 
In addition, increased skin blood circulation, lymphatic 
drainage and hyperpolarization reduce edema (12).
Based on the results of this study and other investiga-
tions, it can be concluded that low level laser therapy 
reduces the length of recovery time and pain level and 
promotes the healing process compared to acyclovir.
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